{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:06:53Z","timestamp":1792822013841,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"DOI":"10.1007\/s40520-025-03048-x","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T02:43:08Z","timestamp":1747104188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cost-effectiveness of opportunistic osteoporosis screening using chest radiographs with deep learning in Germany"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6290-752X","authenticated-orcid":false,"given":"Jean-Yves","family":"Reginster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Schmidmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majed","family":"Alokail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4274-9258","authenticated-orcid":false,"given":"Mickael","family":"Hiligsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"issue":"9","key":"3048_CR1","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1007\/s40520-023-02478-9","volume":"35","author":"C Beaudart","year":"2023","unstructured":"Beaudart C, Demonceau C, Sabico S, Veronese N, Cooper C, Harvey N et al (2023) Efficacy of osteoporosis Pharmacological treatments in men: a systematic review and meta-analysis. Aging Clin Exp Res 35(9):1789\u20131806","journal-title":"Aging Clin Exp Res"},{"issue":"1","key":"3048_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11657-020-0706-y","volume":"15","author":"F Borgstrom","year":"2020","unstructured":"Borgstrom F, Karlsson L, Ortsater G, Norton N, Halbout P, Cooper C et al (2020) Fragility fractures in Europe: burden, management and opportunities. Arch Osteoporos 15(1):59","journal-title":"Arch Osteoporos"},{"issue":"1","key":"3048_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11657-020-00871-9","volume":"16","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M et al (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16(1):82","journal-title":"Arch Osteoporos"},{"issue":"1","key":"3048_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11657-024-01380-9","volume":"19","author":"P Hadji","year":"2024","unstructured":"Hadji P, Esterberg E, Obermuller D, Bartsch R (2024) Bone evaluation study-2: update on the epidemiology of osteoporosis in Germany. Arch Osteoporos 19(1):26","journal-title":"Arch Osteoporos"},{"issue":"2","key":"3048_CR5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/jbmr.4477","volume":"37","author":"M Jang","year":"2022","unstructured":"Jang M, Kim M, Bae SJ, Lee SH, Koh JM, Kim N (2022) Opportunistic osteoporosis screening using chest radiographs with deep learning: development and external validation with a cohort dataset. J Bone Min Res 37(2):369\u2013377","journal-title":"J Bone Min Res"},{"issue":"10","key":"3048_CR6","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1007\/s00198-024-07179-1","volume":"35","author":"A Paderno","year":"2024","unstructured":"Paderno A, Ataide Gomes EJ, Gilberg L, Maerkisch L, Teodorescu B, Koc AM, Meyer M (2024) Artificial intelligence-enhanced opportunistic screening of osteoporosis in CT scan: a scoping review. Osteoporos Int 35(10):1681\u20131692","journal-title":"Osteoporos Int"},{"issue":"1","key":"3048_CR7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s40520-023-02682-7","volume":"36","author":"M Hiligsmann","year":"2024","unstructured":"Hiligsmann M, Silverman SL, Singer AJ, Pearman L, Wang Y, Caminis J, Reginster JY (2024) Comparison of the cost-effectiveness of sequential treatment with abaloparatide in US men and women at very high risk of fractures. Aging Clin Exp Res 36(1):14","journal-title":"Aging Clin Exp Res"},{"key":"3048_CR8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00393-024-01495-x","volume":"83","author":"A Pfeil","year":"2024","unstructured":"Pfeil A, Lange U (2024) Update DVO-Leitlinie 2023 \u201eprophylaxe, diagnostik und therapie der osteoporose Bei postmenopausalen Frauen und Bei M\u00e4nnern Ab dem 50. Lebensjahr\u2013 Was Ist Neu f\u00fcr die rheumatologie?? [Update on the DVO Guideline 2023 Prophylaxis, diagnosis and treatment of osteoporosis in postmenopausal women and in men aged over 50-What\u2019s new for rheumatology?]. Z Rheumatol 83:401\u2013406","journal-title":"Z Rheumatol"},{"issue":"1","key":"3048_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40520-024-02826-3","volume":"36","author":"N Veronese","year":"2024","unstructured":"Veronese N, Briot K, Guanabens N, Albergaria BH, Alokail M, Al-Daghri N et al (2024) Recommendations for the optimal use of bone forming agents in osteoporosis. Aging Clin Exp Res 36(1):167","journal-title":"Aging Clin Exp Res"},{"issue":"3","key":"3048_CR10","first-page":"334","volume":"26","author":"M Hiligsmann","year":"2020","unstructured":"Hiligsmann M, Reginster JY, Silverman S (2020) The value of a Patient-Level modeling approach and need for better reporting in economic evaluations of osteoporosis. J Manag Care Spec Pharm 26(3):334\u2013335","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"3048_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00198-018-4744-x","volume":"30","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Reginster JY, Tosteson ANA, Bukata SV, Saag KG, Gold DT et al (2019) Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts\u2019 consensus meeting organized by the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO) and the US branch of the international osteoporosis foundation. Osteoporos Int 30(1):45\u201357","journal-title":"Osteoporos Int"},{"issue":"1","key":"3048_CR12","doi-asserted-by":"publisher","first-page":"ziae138","DOI":"10.1093\/jbmrpl\/ziae138","volume":"9","author":"JY Reginster","year":"2025","unstructured":"Reginster JY, Silverman SL, Alokail M, Al-Daghri N, Hiligsmann M (2025) Cost-effectiveness of radiofrequency echographic multi-spectrometry for the diagnosis of osteoporosis in the united States. JBMR Plus 9(1):ziae138","journal-title":"JBMR Plus"},{"issue":"1","key":"3048_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C et al (2022) Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health 25(1):3\u20139","journal-title":"Value Health"},{"issue":"6","key":"3048_CR14","doi-asserted-by":"publisher","first-page":"380","DOI":"10.7326\/0003-4819-152-6-201003160-00008","volume":"152","author":"P Haentjens","year":"2010","unstructured":"Haentjens P, Magaziner J, Colon-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S (2010) Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152(6):380\u2013390","journal-title":"Ann Intern Med"},{"key":"3048_CR15","doi-asserted-by":"crossref","unstructured":"Bleibler F, Rapp K, Jaensch A, Becker C, K\u00f6nig HH (2014) Expected lifetime numbers and costs of fractures in postmenopausal women with and without osteoporosis in Germany: a discrete event simulation model. Bmc Health Serv Res.;14","DOI":"10.1186\/1472-6963-14-284"},{"key":"3048_CR16","doi-asserted-by":"publisher","first-page":"115286","DOI":"10.1016\/j.bone.2020.115286","volume":"134","author":"E Soreskog","year":"2020","unstructured":"Soreskog E, Strom O, Spangeus A, Akesson KE, Borgstrom F, Banefelt J et al (2020) Risk of major osteoporotic fracture after first, second and third fracture in Swedish women aged 50 years and older. Bone 134:115286","journal-title":"Bone"},{"issue":"3","key":"3048_CR17","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.semarthrit.2020.02.004","volume":"50","author":"M Hiligsmann","year":"2020","unstructured":"Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss R, Reginster JY (2020) Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective. Semin Arthritis Rheum 50(3):394\u2013400","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"3048_CR18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s00198-003-1516-y","volume":"15","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15(2):108\u2013112","journal-title":"Osteoporos Int"},{"issue":"5","key":"3048_CR19","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S8756-3282(03)00061-9","volume":"32","author":"JA Kanis","year":"2003","unstructured":"Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32(5):468\u2013473","journal-title":"Bone"},{"key":"3048_CR20","unstructured":"IQWIQ General methods. Version 6.1 of 24 January 2022. Accesible at: https:\/\/www.iqwig.de\/methoden\/general-methods_version-6-1.pdf"},{"issue":"9","key":"3048_CR21","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00198-019-05064-w","volume":"30","author":"A Svedbom","year":"2019","unstructured":"Svedbom A, Hadji P, Hernlund E, Thoren R, McCloskey E, Stad R, Stollenwerk B (2019) Cost-effectiveness of Pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the united Kingdom. Osteoporos Int 30(9):1745\u20131754","journal-title":"Osteoporos Int"},{"issue":"8","key":"3048_CR22","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.jamda.2015.05.013","volume":"16","author":"K Rapp","year":"2015","unstructured":"Rapp K, Rothenbacher D, Magaziner J, Becker C, Benzinger P, Konig HH et al (2015) Risk of nursing home admission after femoral fracture compared with stroke, myocardial infarction, and pneumonia. J Am Med Dir Assoc 16(8):715 e7- e12","journal-title":"J Am Med Dir Assoc"},{"issue":"1","key":"3048_CR23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12955-021-01719-7","volume":"19","author":"O Marten","year":"2021","unstructured":"Marten O, Greiner W (2021) EQ-5D-5L reference values for the German general elderly population. Health Qual Life Outcomes 19(1):76","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"3048_CR24","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s10198-019-01054-1","volume":"20","author":"T Grochtdreis","year":"2019","unstructured":"Grochtdreis T, Dams J, Konig HH, Konnopka A (2019) Health-related quality of life measured with the EQ-5D-5L: Estimation of normative index values based on a representative German population sample and value set. Eur J Health Econ 20(6):933\u2013944","journal-title":"Eur J Health Econ"},{"issue":"3","key":"3048_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00198-017-4317-4","volume":"29","author":"A Svedbom","year":"2018","unstructured":"Svedbom A, Borgstom F, Hernlund E, Strom O, Alekna V, Bianchi ML et al (2018) Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures-results from the ICUROS. Osteoporos Int 29(3):557\u2013566","journal-title":"Osteoporos Int"},{"issue":"15","key":"3048_CR26","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417\u20131427","journal-title":"N Engl J Med"},{"issue":"1","key":"3048_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.clinthera.2021.11.015","volume":"44","author":"D Willems","year":"2022","unstructured":"Willems D, Javaid MK, Pinedo-Villanueva R, Libanati C, Yehoshua A, Charokopou M (2022) Importance of time Point-Specific indirect treatment comparisons of osteoporosis treatments: A systematic literature review and network Meta-Analyses. Clin Ther 44(1):81\u201397","journal-title":"Clin Ther"},{"issue":"7","key":"3048_CR28","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00198-024-07043-2","volume":"35","author":"E Gielen","year":"2024","unstructured":"Gielen E, Aldven M, Kanis JA, Borgstrom F, Senior E, Willems D (2024) Cost-effectiveness of Romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium. Osteoporos Int 35(7):1173\u20131183","journal-title":"Osteoporos Int"},{"issue":"10","key":"3048_CR29","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1007\/s00198-016-3623-6","volume":"27","author":"P Hadji","year":"2016","unstructured":"Hadji P, Kyvernitakis I, Kann PH, Niedhart C, Hofbauer LC, Schwarz H et al (2016) GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporos Int 27(10):2967\u20132978","journal-title":"Osteoporos Int"},{"issue":"12","key":"3048_CR30","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1007\/s00198-024-07251-w","volume":"35","author":"F Borgstrom","year":"2024","unstructured":"Borgstrom F, Lorentzon M, Johansson H, Harvey NC, McCloskey E, Willems D et al (2024) Cost-effectiveness intervention thresholds for Romosozumab and teriparatide in the treatment of osteoporosis in the UK. Osteoporos Int 35(12):2183\u20132193","journal-title":"Osteoporos Int"},{"issue":"10","key":"3048_CR31","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1002\/hec.3085","volume":"24","author":"L Ryen","year":"2015","unstructured":"Ryen L, Svensson M (2015) The willingness to pay for a quality adjusted life year: A review of the empirical literature. Health Econ 24(10):1289\u20131301","journal-title":"Health Econ"},{"key":"3048_CR32","doi-asserted-by":"publisher","first-page":"115833","DOI":"10.1016\/j.bone.2020.115833","volume":"144","author":"NR Fuggle","year":"2021","unstructured":"Fuggle NR, Curtis B, Clynes M, Zhang J, Ward K, Javaid MK et al (2021) The treatment Gap: the missed opportunities for osteoporosis therapy. Bone 144:115833","journal-title":"Bone"},{"issue":"5","key":"3048_CR33","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s00223-024-01196-2","volume":"114","author":"MG Bendtsen","year":"2024","unstructured":"Bendtsen MG, Hitz MF (2024) Opportunistic identification of vertebral compression fractures on CT scans of the chest and abdomen, using an AI algorithm, in a Real-Life setting. Calcif Tissue Int 114(5):468\u2013479","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"3048_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11657-024-01372-9","volume":"19","author":"T Asamoto","year":"2024","unstructured":"Asamoto T, Takegami Y, Sato Y, Takahara S, Yamamoto N, Inagaki N et al (2024) External validation of a deep learning model for predicting bone mineral density on chest radiographs. Arch Osteoporos 19(1):15","journal-title":"Arch Osteoporos"},{"key":"3048_CR35","doi-asserted-by":"crossref","unstructured":"Sato Y, Yamamoto N, Inagaki N, Iesaki Y, Asamoto T, Suzuki T, Takahara S (2022) Deep learning for bone mineral density and T-Score prediction from chest X-rays: A multicenter study. Biomedicines.;10(9)","DOI":"10.3390\/biomedicines10092323"},{"issue":"4","key":"3048_CR36","doi-asserted-by":"publisher","first-page":"300060524124475","DOI":"10.1177\/03000605241244754","volume":"52","author":"Y He","year":"2024","unstructured":"He Y, Lin J, Zhu S, Zhu J, Xu Z (2024) Deep learning in the radiologic diagnosis of osteoporosis: a literature review. J Int Med Res 52(4):3000605241244754","journal-title":"J Int Med Res"},{"key":"3048_CR37","doi-asserted-by":"publisher","first-page":"1222041","DOI":"10.3389\/fendo.2023.1222041","volume":"14","author":"S Ruhling","year":"2023","unstructured":"Ruhling S, Schwarting J, Froelich MF, Loffler MT, Bodden J, Hernandez Petzsche MR et al (2023) Cost-effectiveness of opportunistic QCT-based osteoporosis screening for the prediction of incident vertebral fractures. Front Endocrinol (Lausanne) 14:1222041","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"3048_CR38","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40273-022-01239-2","volume":"41","author":"N Li","year":"2023","unstructured":"Li N, Beaudart C, Cauley JA, Ing SW, Lane NE, Reginster JY et al (2023) Cost effectiveness analyses of interventions for osteoporosis in men: A systematic literature review. PharmacoEconomics 41(4):363\u2013391","journal-title":"PharmacoEconomics"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-025-03048-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-025-03048-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-025-03048-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T02:43:11Z","timestamp":1747104191000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-025-03048-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3048"],"URL":"https:\/\/doi.org\/10.1007\/s40520-025-03048-x","relation":{},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JYR has received consulting fees from Promedius. RS is president of the German osteology association (DVO Dachverband Osteologie) and member of the DVO guideline committee for osteoporosis. He received consultancy funding from Alexion, Amgen, Sandoz and UCB, speeking fees from Alexion, Amgen, Blueprint, Takeda\/Shire, Theramex and UCB. MA has no conflict of interest relevant to this paper. MH has received research grants (paid to institution) from Radius Health, and Angelini Pharma, lecture fees from IBSA (paid to institution) and Echolight, and was grant advisor for Pfizer (paid to institution) and consultant (paid to institution) for Gr\u00fcnenthal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}